H3K27M-MUTANT DIFFUSE MIDLINE GLIOMA

Clinical trials for H3K27M-MUTANT DIFFUSE MIDLINE GLIOMA explained in plain language.

Never miss a new study

Get alerted when new H3K27M-MUTANT DIFFUSE MIDLINE GLIOMA trials appear

Sign up with your email to follow new studies for H3K27M-MUTANT DIFFUSE MIDLINE GLIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet finished but already full! 1

Immune cells take on deadly childhood brain cancer

Disease control Recruiting now

This early-stage trial tests whether a new immune cell therapy called GD2 CAR T cells can be safely made and given to children and adults with a rare, aggressive brain tumor called H3K27M-mutant diffuse midline glioma. The study aims to find the right dose and check for side effe…

Matched conditions: H3K27M-MUTANT DIFFUSE MIDLINE GLIOMA

Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control

Last updated Jun 27, 2026 08:14 UTC

H3K27M-MUTANT DIFFUSE MIDLINE GLIOMA

Get alerted when new H3K27M-MUTANT DIFFUSE MIDLINE GLIOMA trials appear

Immune cells take on deadly childhood brain cancer